RxDoctor Payments Data

Deborah Goreham

Family · Tuolumne, CANPI 1083014559

Payments from drug & device makers

$1,005in general payments, 2019–2025

Across 47 payments — averaging $21.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$269
  • Lundbeck LLC$147
  • Novo Nordisk$108
  • Otsuka America Pharmaceutical, Inc.$53
  • AbbVie$51
  • Lilly USA, LLC$42
  • plus $334 from 14 others

What the payments were for

  • Food & beverage$1,005100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,005 in reported general payments places this provider in the 70th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$111,165
Medicare patients
217
Services billed
2,073

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$58,999
JardianceEmpagliflozin33$37,961
SublocadeBuprenorphine16$36,246
EliquisApixaban42$35,847
Breo ElliptaFluticasone/Vilanterol43$19,407
XareltoRivaroxaban13$18,893
RexultiBrexpiprazole11$15,921
LinzessLinaclotide15$14,597
RybelsusSemaglutide11$9,199
Varenicline Tartrate19$6,282
Spiriva HandihalerTiotropium Bromide13$6,276
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen267$4,283
Buprenorphine Hcl39$4,032
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl31$2,799
Levothyroxine Sodium131$2,481

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$108$68,19878 claims
Indivior Inc.Sublocade$25$36,24616 claims
Johnson & JohnsonXarelto$31$18,89313 claims
Otsuka America Pharmaceutical, Inc.Rexulti$53$15,92111 claims
AbbVieLinzess$51$14,59715 claims
Lilly USA, LLCOlanzapine$42$90118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,634 family providers in California.

Other family in Tuolumne

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →